Company: ZLAB
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001628280-25-008409
Chunk: 68

Company: Zai Lab Ltd
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 68
---
 Amado, the Company’s President and Head of Global Research and Development, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 9,000 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than December 17, 2025.On November 22, 2024, F. Ty Edmondson, the Company’s Chief Legal Officer, adopted a new written Rule 10b5-1 trading arrangement for the sale of up to 28,872 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 21, 2025.

Other than as described above, during the fourth quarter of 2024, none of our directors or executive officers (as defined in Rule 16a-1(f) under the Exchange Act) has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K).

-89-

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not applicable.

-90-

PART III

Item 10. Directors, Executive Officers and Corporate Governance

The Company has adopted insider trading policies and procedures governing the purchase, sale, and/or other dispositions of our securities by directors, officers, employees, or the Company itself that we believe are reasonably designed to promote compliance with applicable insider trading laws, rules, regulations, and listing standards. Additional information required by this item will be set forth in the 2025 Proxy Statement and is incorporated herein by reference. 

Item 11. Executive Compensation 

The information required by this item will be set forth in the 2025 Proxy Statement and is incorporated herein by reference. 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 

The information required by this item will be set forth in the 2025 Proxy Statement and is incorporated herein by reference. 

Item 13. Certain Relationships and Related Transactions, and Director Independence 

The information required by this item will be set forth in the 2025 Proxy Statement and is incorporated herein by reference. 

Item 14. Principal Accounting Fees and Services 

The information required by this item will be set forth in the 2025 Proxy Statement and is incorporated herein by reference.

-91-

PART IV

Item 15. Exhibits, Financial Statement Schedules

The financial statements listed in